drugset
drugset / Trial / NCT06259383

Oral Ivermectin for Chikungunya Viral Infection

NCT06259383 ↗

Phase 3 Completed 120 enrolled Prince of Songkla University
RandomizedParallel-groupSingle-blindTreatment

Summary

Chikungunya viral infection (CVI) is a mosquito-borne infection, caused by chikungunya virus (CHIKV), an alphavirus, belonging to the family Togaviridae. This infection causes febrile illness associated with high fever, rash, acute deliberating and persistent arthralgia. There is no licensed vaccine or specific treatment for this infection. Ivermectin (IVM), commonly-used antiparasitic, has been demonstrated to inhibit replication of CHIKV.

Timeline

Start
2018-01-01
Primary completion
2021-12-31
Completion
2024-01-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Ivermectin Small molecule 400 ug/kg Oral

Indications

No indication recorded.